Conserved internal influenza virus antigen

**Conserved internal influenza virus antigens** refer to the internal structural and functional proteins of the influenza virus that exhibit low sequence variability across different strains and subtypes, such as nucleoprotein (NP) and matrix proteins (M1 and M2). Unlike the highly variable external viral antigens hemagglutinin (HA) and neuraminidase (NA), these internal antigens remain largely unchanged among circulating influenza A virus strains and are crucial for viral replication, assembly, and structure[2][4][7]. Because of their conservation, they are targets for cross-protective immunity, especially cytotoxic T lymphocyte–mediated responses and, to a lesser extent, broadly reactive antibodies (notably to the M2 ectodomain, M2e). While these antigens have limited natural humoral protective efficacy, vaccine strategies targeting them are under development to achieve universal influenza immunity through T cell or cross-reactive antibody responses, and some experimental monoclonal antibody therapies that target these antigens have shown broad protective effects in preclinical models[4][7]. **Key antigens included:** - **Nucleoprotein (NP):** Encapsulates viral RNA and is involved in viral genome replication; highly conserved and a dominant target of CD8+ T cell responses[2][7]. - **Matrix protein 1 (M1):** Provides structure to the virion and mediates assembly and budding[2]. - **Matrix protein 2 (M2, especially M2e):** Small ion channel protein essential for viral uncoating, and its extracellular domain (M2e) is highly conserved and can be targeted by broadly cross-reactive protective antibodies[4][5]. **Therapeutic targeting:** - **M2 ion channel inhibitors** (amantadine, rimantadine) were early antiviral drugs but are now largely ineffective due to widespread resistance[5]. - **Broadly neutralizing monoclonal antibodies** against M2e are in development for universal flu therapy, showing protection against multiple influenza A subtypes in preclinical models[4]. - **Vaccines** aimed at these targets are in research to provide universal, cross-strain protection by inducing T cell immunity or broad antibody responses[2][7].

Other names

Nucleoprotein (NP)Matrix protein 1 (M1)Matrix protein 2 (M2, including M2e)Internal antigens of influenza virus

Inhibition of viral replication (via ion channel inhibition for M2), neutralization by antibody binding to block viral assembly, fusion, or uncoating steps (passive immunity), induction of T cell responses to infected cells